Treatment of comorbid chronic obstructive pulmonary disease and cardiovascular disease
https://doi.org/10.18093/0869-0189-2016-26-3-364-371
Abstract
This review provided recent information about treatment of patients with comorbid respiratory and cardiovascular disease. Cardiorespiratory comorbidity is associated with cross"deterioration of the disease course given similar pathogenic components. This could decrease effects of treatment, worsen prognosis and actually requires new approaches to diagnosis and therapy. While choosing the treatment strategy for a patient with comorbid chronic obstructive pulmonary disease (COPD) and cardiovascular disease, a physician should be aware of the pooled risk of adverse events. Some agents widely used for treatment of cardiovascular diseases could worsen the course of COPD and, vice versa, bronchodilators that are the essential component of therapy of chronic obstructive bronchitis could adversely affect the cardiovascular system. Therefore, medication choice could be significantly limited due to comorbidity.
About the Authors
N. T. Vatutin
M.Gor'kiy Donetsk National State Medical University: 14, Il'icha av., Donetsk ,83005, Ukraine
V.K.Gusak State Institute of Urgent and Reconstructive Surgery, National Medical Science Academy of Ukraine: 47, Leninskiy av., Donetsk, 83000, Ukraine
Russian Federation
Russian Federation
MD, Professor, Head of Department of Hospital Internal Medicine, M.Gor'kiy Donetsk National Medical University; Alternate Head of Division of Urgent and Reconstructive Cardiosurgery, V.K.Gusak’ State Institute of Urgent and Reconstructive Surgery; National Medical Science Academy of Ukraine; tel.: (38062) 3850517
A. S. Smirnova
M.Gor'kiy Donetsk National State Medical University: 14, Il'icha av., Donetsk ,83005, Ukraine
Russian Federation
Russian Federation
PhD, Assistant Lecturer at Department of Hospital Internal Medicine, M.Gor'kiy Donetsk National Medical University; tel.: (38062) 3850517
References
1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Global Initiative for Chronic Obstructive lung Disease (GOLD). The updated 2015 report is available on www.goldcopd.com).
2. Kryukov N.N., Shanina I.Yu., Protasov A.D. Results of functional testing of patients with comorbid coronary artery disease and chronic obstructive pulmonary disease. Fundamental'nye issledovaniya. 2011; 2: 83–88 (in Russian).
3. Sin D.D., Man S.F.P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2: 8–11.
4. Kubazhi Kh. A course and prognosis of patients with comorbidity of chronic obstructive pulmonary disease, coronary artery disease and hypertension: Diss. Ryazan'; 2013 (in Russian).
5. Vakhnenko A.V. Current approach to treatment of comorbid chronic obstructive pulmonary disease and chronic heart failure. Svіt meditsini ta bіologії. 2013; 3: 70–73 (in Ukranian).
6. Gurova A.Yu., Chaplygin A.V., Svet A.V. et al. The optimal pharmacotherapy with beta"blockers in comorbidity of coronary artery disease and chronic obstructive pulmonary disease. Lechashchiy vrach. 2012; 2 (in Russian).
7. Short P.M., Lipworth S.I., Elder D.H. et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. Br. Med. J. 2011; 342: d2549.
8. Rasmussen D.B., Lange P., Jensen M.T. Patients with chronic obstructive pulmonary disease and heart disease can benefit from beta"blocker treatment. Ugeskr. Laeger. 2015; 177 (38): V02150184.
9. Statsenko M.E., Derevyanchenko M.V. Effects of beta"blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease. Farmateka. 2013; 15: 9–15 (in Russian).
10. Bhatt S.P., Wells J.M., Kinney G.L. et al. β"Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016; 71 (1): 8–14.
11. Andell P., Erlinge D., Smith J.G. et al. β"Blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J. Am. Heart Ass. 2015; 4: e001611.
12. Kubota Y., Asai K., Furuse E. et al. Impact of β"blocker selectivity on long"term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 515–523.
13. Martiniuc C., Branishte T. The use of beta blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2012; 116 (1): 218–221.
14. Frans H. Rutten. β"Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 2010; 170 (10): 880–887.
15. Malerba M., Montuschi P., Radaeli A., Pirisi M. Role of betablockers in patients with COPD: current perspective. Drug Discov. Today. 2015; 20 (1): 129–135.
16. Mascitelli L., Pezzetta F. Inhibition Of the renin"angiotensin system in patients with COPD and pulmonary hypertensionresponse. Chest. 2007; 131 (3): 938– 939.
17. Zhang H., Li Y., Zeng Y. et al. Endothelin"1 downregulates angiotensin"converting enzyme"2 expression in human bronchial epithelial cells. Pharmacology. 2013; 91 (5–6): 297–304.
18. Martiniuc C., Braniste A., Braniste T. Angiotensin converting enzyme inhibitors and pulmonary hypertension. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2012; 116 (4): 1016–1020.
19. Petersen H., Sood A., Meek P.M. et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin"converting enzyme inhibitor use. Chest. 2014; 145 (4): 695–703.
20. Orlov V.A., Gilyarevskiy S.R., Urusbieva D.M., Daurbekova L.V. A role of adverse effects of angiotensin"converting enzyme inhibitors for a choice of therapeutic strategy in patients with cardiovascular diseases. Rossiyskiy kardiologicheskiy zhurnal. 2005; 3: 79–91 (in Russian).
21. Evdokimova A.G., Evdokimov V.V., Radzevich A.E., Ol'khin V.A. A role of nitrates for treatment of cardiovascular diseases: evidence and real clinical practice. Spravochnik poliklinicheskogo vracha. 2013; 2: 24–29 (in Russian).
22. Girard A., Jouneau S., Chabanne C. et al. Severe pulmonary hypertension associated with COPD: Hemodynamic improvement with specific therapy. Respiration. 2015; 90 (3): 220–228.
23. Chandy D., Aronow W.S., Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr. Blood Press. Control. 2013; 6: 101–109.
24. Yakhontov D.A., Balabanova N.F. Effects of the 3rd generation calcium antagonists for treatment of patients with comorbid hypertension and chronic obstructive pulmonary disease. Ratsional'naya farmakoterapiya v kardiologii. 2010; 6 (3): 339–344 (in Russian).
25. Sharif"Kashani B., Hamraghani A., Salamzadeh J. et al. The effect of amlodipine and sildenafil on the NT"ProBNP level of patients with COPD"induced pulmonary hypertension. Iran. J. Pharm. Res. 2014; 13: 161–168.
26. Vatutin N.T., Shevelek A.N., Degtyareva A.E., Kasem S.S. Hyperaldosteronism and perspectives of aldosterone antagonists in resistant hypertension. Zhurnal natsional'noy akademii meditsinskikh nauk. 2014; 20 (1): 43–52 (in Russian).
27. Głuszek J. Ischaemic heart disease and hypertension in patients with chronic obstructive pulmonary disease andobstructive sleep apnoea. Pneumonol. Alergol. Pol. 2013; 81 (6): 567–574.
28. Bahammam A. Obstructive sleep apnea: from simple upper airway obstruction to systemic inflammation. Ann. Saudi. Med. 2011; 31: 1–3.
29. Lee R., McNicholas W.T. Obstructive sleep apnea in chronic obstructive pulmonary disease patients. Curr. Opin. Pulm. Med. 2011; 17: 79–83.
30. Curkendall S.M., DeLuise C., Jones J.K. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006; 16: 63–70.
31. Korreya L.L., Lebedev T.Yu., Efremova O.A. et al. A problem of comorbidity of chronic obstructive pulmonary disease and some cardiovascular diseases. Nauchnye vedomosti BelGU. Seriya: Meditsina. Farmatsiya. 2013; 4 (147): 12–17 (in Russian).
32. Sheng X., Murphy M.J., MacDonald T.M. Effect of statins on total cholesterol concentrations, cardiovascular morbidity, and all"cause mortality in chronic obstructive pulmonary disease: a population"based cohort study. Clin. Ther. 2012; 34: 374–384.
33. Lawes C.M., Thornley S., Young R. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. J. 2012; 21: 35–40.
34. Cao C., Wu Y., Xu Z. et al. The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta"analysis of observational research. Sci. Rep. 2015; 5: 16461.
35. Blamoun A.I., Batty G.N., DeBari V.A. et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract. 2008; 62: 1373–1378.
36. Huang C.C., Chan W.L., Chen Y.C. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population"based cohort study in Taiwan. Clin. Ther. 2011; 33: 1365–1370.
37. Jiang X., Yuan L., Li P. et al. Effect of simvastatin on 5"HT and 5"HTT in a rat model of pulmonary artery hypertension. Cell. Physiol. Biochem. 2015; 37 (5): 1712–1724.
38. Kurlyanskaya E.K., Atroshchenko E.S., Gevorkyan T.T., Denisevich T.L. Aspirin as a component of antiplatelet therapy of cardiovascular diseases. Meditsinskie novosti. 2007; 8: 46–48 (in Russian).
39. Sin D.D. The devastating power of platelets in COPD exacerbations: can aspirin save lives in COPD? Thorax. 2014; 69 (7): 603–604.
40. Harrison M.T., Short P., Williamson P.A. et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014; 69 (7): 609–615.
41. Winning J., Reichel J., Eisenhut Y. et al. Anti"platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009; 20: 50–57.
42. Cooper"DeHoff R.M., Handberg E.M., Mancia G.Q. et al. INVEST revisited: review of findings from the International Verapamil SR"Trandolapril Study. Exp. Rev. Cardiovasc. Ther. 2009; 7 (11): 1329–1340.
43. Diaz A. Long"term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 2005; 26: 967–974.
44. Salpeter S.R. Cardiovascular safety of beta(2)"adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging. 2004; 21 (6): 405–414.
45. Calverley P.M.A., Anderson J.A., Celli B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.
46. Ferri C. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease. High Blood Press Cardiovasc. Prev. 2015; 22 (2): 103–111.
47. Provotorov V.M., Kotochigova T.V. Pharmacotherapy of chronic obstructive pulmonary disease and chronic heart failure. Molodoy uchenyy. 2011; 6 (2): 187–189 (in Russian).
48. Terekhova E.P., Terekhov D.V. A role of phosphodiesterase 4 inhibitor roflumilast in treatment of chronic obstructive pulmonary disease. Trudnyy patsient. 2014; 10 (12): 44–51 (in Russian).
49. Herych P.R., Iatsyshyn R.I. Treatment and prevention of combined cardio"respiratory pathology in exacerbation of chronic obstructive pulmonary disease (new approach). Lik. Sprava. 2014; (7–8): 38–46 (in Ukrainian).
Review
For citations:
Vatutin N.T., Smirnova A.S. Treatment of comorbid chronic obstructive pulmonary disease and cardiovascular disease. PULMONOLOGIYA. 2016;26(3):364-371. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-3-364-371
Views:
2154
Email this article 